Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05638399
Other study ID # ShenzhenPH spine06
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date January 15, 2020
Est. completion date February 28, 2023

Study information

Verified date February 2023
Source Shenzhen People's Hospital
Contact Hongyu Wang, Doctor
Phone 18241651300
Email wanghongyu790039663@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study was to compare denosumab and zoledronate efficacy in bone mass, bone turnover markers (BTMs), Visual Analogue Scale (VAS) for leg and back, EuroQol Five-Dimension (EQ-5D) scores, Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31) scores, and Roland-Morris Disability Functioning Questionnaire (RMDQ) scores, secondary fracture, complications and adverse events after lumbar fusion.


Description:

Lumbar degenerative disease including spinal stenosis and lumbar spondylolisthesis were the most common reason lead to older patients disability, which was the main indication for older patients to perform lumbar fusion surgery. For patients with lumbar degenerative disease older than 50 years old, a proportion of patients had osteoporosis. The trial aims to investigate whether denosumab versus zoledronate acid in osteopenic patients with lumbar fusion surgery.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date February 28, 2023
Est. primary completion date February 26, 2023
Accepts healthy volunteers No
Gender All
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria: - Participants aged 40 to 85 years - who diagnosed with lumbar spinal stenosis or lumbar spondylolisthesis - osteopenia with BMD T score between -1 and -2.5 via dual energy X-ray - low back pain or leg numbness or weakness - MRI demonstrated signs of nerve compression - patients with one or two level symptoms. Exclusion Criteria: - cauda equina syndrome - progressive neurologic deficit - history of cancer - scoliosis greater than 15° - back open surgery history - have contraindications for surgery - who had anti-osteoporosis medication within 6 weeks

Study Design


Intervention

Drug:
Denosumab 60 mg/ml [Prolia]
60 mg subcutaneously per 6 month
Zoledronate
5mg, intravenous infusion once a year

Locations

Country Name City State
China ShenzhenPH Shenzhen Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Shenzhen People's Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Lumbar bone mineral density(BMD) Lumbar vertebral (L1 to L4, except the surgery segment) BMD were determined at baseline, 6 and 12 months via dual energy X-ray up to 12 months
Primary Total hip BMD Total hip BMD were determined at baseline, 6 and 12 months via dual-energy X-ray up to 12 months
Primary Femoral neck BMD Femoral neck BMD were determined at baseline, 6 and 12 month via dual-energy X-ray up to 12 months
Primary Procollagen type 1 n-terminal propeptide (P1NP) Bone formation marker, P1NP were determined at baseline, 6 and 12 months after surgery up to 12 months
Primary C-terminal cross-linked type 1 collagen terminal peptide (CTX) Bone resorption marker, CTX were determined at baseline, 6 and 12 months after surgery up to 12 months
Primary Visual analog scale (VAS) back The VAS score for back pain were determined at baseline, 6 and 12 month. Use a ruler about 10cm long, one side is marked with "0" and the other "10" respectively. A score of 0 indicates no pain, 10 indicates the most unbearable pain. up to 12 months
Secondary The Roland-Morris Disability Questionnaire The Roland-Morris Disability Questionnaire is scored by 24 adding up the number of items checked "yes" on different low back pain-related daily activity disabilities. Total scores range from 0 to 24, with higher scores 24 indicating a higher level of disability related to low back pain and lowest 0 represents no back pain. up to 12 month
Secondary The QUALEFFO-31 Questionnaire The Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 (QUALEFFO-31), which contains three domains including pain, physical function, and mental function. This scale is assessed on a scale of 0 to 100, with 0 indicating the highest QoL and 100 the lowest. up to 12 month
Secondary The EQ-5D Questionnaire The EuroQol five-dimension (EQ-5D) questionnaire evaluates health status consisting five dimensions: mobility, selfcare, performance of usual activities, pain or discomfort, and anxiety or depression. After conversion, the index was between 0 and 1.0 (minimum score: 0, indicating worst health state; full score:1.0, indicating full health). up to 12 month
Secondary New fracture rate New fracture rate containing vertebral fracture and non-vertebral fracture was assessed at 12 month after surgery. The lowest score was 0, the highest score was 100%. The lower score 0 represents no secondary fracture. up to 12 month
Secondary Complications Complications including cage subsidence, pedicle screw loosening, infection, peripheral nerve injury, and recurrent symptoms were assessed. up to 12 month
Secondary Adverse events The main adverse events including deep venous thrombosis, pneumonia, acute renal failure, pulmonary embolism, myocardial infarction, influenza, transfer to intensive care unit, joint pain, headache, nausea, osteonecrosis of the jaw, atypical femoral fracture and rash. up to 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Active, not recruiting NCT05066477 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Bone Mass Among Osteopenic Women N/A
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Completed NCT01439139 - Bone UltraSonic Scanner (BUSS): Validation Study N/A
Not yet recruiting NCT01397838 - Safety Study of an Oral Pro-boneTM, Administered to Post Menopausal Osteopenic Women Phase 1
Completed NCT01222026 - Systematic Treatment After Successful Surgical Treatment for Primary Hyperparathyroidism With Strontium Ranelate Phase 4
Completed NCT01152580 - Melatonin Osteoporosis Prevention Study Phase 1
Completed NCT00789425 - Investigating the Effect of Standardized Olive Extract on Bone Turnover Markers in Postmenopausal Women Phase 2
Completed NCT00463268 - Osteoporosis Prevention With Low Dose Alendronate Phase 3
Completed NCT00655681 - Prevention of Post Operative Bone Loss in Children N/A
Completed NCT00798473 - Zoledronate for Osteopenia in Pediatric Crohn's Phase 3
Active, not recruiting NCT00076050 - Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms Phase 3
Completed NCT00226031 - Optimal Management of Women With Wrist Fractures N/A
Enrolling by invitation NCT04752098 - A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method N/A
Completed NCT04720833 - Effect of Dried Plum on Bone and Markers of Bone Status in Men N/A
Recruiting NCT05541432 - Finding the Optimal Resistance Training Intensity For Your Bones N/A
Active, not recruiting NCT05405894 - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Completed NCT05457036 - Evaluation of the Effect of Spry Belt Treatment on Bone Turnover Marker Profile N/A
Completed NCT04040010 - The Effects of Bovine Colostrum in Bone Metabolism in Humans N/A
Completed NCT02731820 - Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia N/A